DDX41 and incontinentia pigmenti: In case of exposure to SARS-CoV-2, IP patients with auto-Abs that do not neutralize IFN-β may benefit from early treatment with IFN-β (Bastard et al., 2021b), monoclonal anti-SARS-CoV-2 antibodies (Lévy et al., 2021), antiviral drugs, or recombinant IFN-λ (Reis et al., 2023).